Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways
S. Michael Rothenberg(Pfizer (United States)), Daniel A. Haber(Howard Hughes Medical Institute), Miguel N. Rivera(University of North Texas), Jeffrey A. Engelman(Cancer Research Center), Gaylor Boulay(Harvard University), Sarah Cullen(University of Arkansas for Medical Sciences), Anthony C. Faber(Virginia Commonwealth University), Elizabeth L. Lockerman(Harvard University), Shyamala Maheswaran(Massachusetts General Hospital), Alexa B. Turke(Harvard University), Kyle Concannon(Harvard University)
Cited by 45